Background: Lung adenocarcinoma (LUAD) is the most prevalent non-small cell lung cancer (NSCLC). Patients with LUAD have a poor 5-year survival rate. The use of immune checkpoint inhibitors (ICIs) for the treatment of LUAD has been on the rise in the past decade. This study explored the prognostic role of butyrophilin-like 9 (BTNL9) in LUAD.
Methods: Gene expression profile of buytrophilins (BTNs) was determined using the GEPIA database. The effect of BTNL9 on the survival of LUAD patients was assessed using Kaplan-Meier plotter and OncoLnc. Correlation between BTNL9 expression and tumor-infiltrating immune cells (TILs) was explored using TIMER and GEPIA databases. Further, the relationship between BTNL9 expression and drug response was evaluated using CARE. Besides, construction and evaluation of nomogram based on BTNL9 expression and TNM stage.
Results: BTNL9 expression was downregulated in LUAD and was associated with a poor probability of 1, 3, 5-years overall survival (OS). In addition, BTNL9 expression was regulated at epigenetic and post-transcriptional modification levels. Moreover, BTNL9 expression was significantly positively correlated with ImmuneScore and ESTIMATEScore. Furthermore, BTNL9 expression was positively associated with infiltration levels of B cells, CD4 T cells, and macrophages. Kaplan-Meier analysis showed that BTNL9 expression in B cells and dendritic cells (DCs) was significantly associated with OS. BTNL9 expression was significantly positively correlated with CARE scores.
Conclusions: These findings show that BTNL9 is a potential prognostic biomarker for LUAD. Low BTNL9 expression levels associated with low infiltration levels of naïve B cells, and DCs in the tumor microenvironment are unfavorable for OS in LUAD patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507344 | PMC |
| http://dx.doi.org/10.1186/s12885-021-08790-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer.
J Transl Med
July 2024
Departments of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, Montebello, 0310, Oslo, Norway.
Article Synopsis
- Patients with colorectal cancer that has spread to the peritoneum (PM-CRC) have a poor prognosis and respond poorly to chemotherapy.
- The study analyzed tumor samples from 230 patients treated with hyperthermic intraperitoneal chemotherapy (HIPEC) to investigate the molecular characteristics of these tumors, revealing that 27% had BRAF mutations, which were linked to significantly lower survival rates.
- BRAF mutations were associated with specific gene expression changes and immune checkpoint molecules, suggesting that targeting Wnt signaling and these immune checkpoints could provide new treatment options for PM-CRC.
LncRNA CALML3-AS1 modulated by mA modification induces BTNL9 methylation to drive non-small-cell lung cancer progression.
Cancer Gene Ther
December 2023
Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan Province, P. R. China.
Non-small cell lung cancer (NSCLC) is a common and lethal malignancy. The carcinogenic roles of lncRNA CALML3 antisense RNA 1 (CALML3-AS1) have been documented. However, the function and potential mechanisms of CALML3-AS1 in the progression of NSCLC need to be further explored.
View Article and Find Full Text PDFComprehensive analysis of BTNL9 as a prognostic biomarker correlated with immune infiltrations in thyroid cancer.
BMC Med Genomics
October 2023
Department of Endocrinology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
Background: Thyroid cancer (THCA) is the most common type of endocrine cancers, and the disease recurrences were usually associated with the risks of metastasis and fatality. Butyrophilin-like protein 9 (BTNL9) is a member of the immunoglobulin families. This study investigated the prognostic role of BTNL9 in THCA.
View Article and Find Full Text PDFDown regulation of Cathepsin W is associated with poor prognosis in pancreatic cancer.
Sci Rep
October 2023
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Article Synopsis
- Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, prompting research into new biomarkers for early diagnosis and survival prediction using RNA and microRNA sequencing alongside machine learning.
- Analysis of gene expression from The Cancer Genome Atlas (TCGA) and survival data identified 23 genes and several microRNAs that affect PDAC progression and patient survival.
- Machine learning techniques, particularly Gradient Boosting Machines, were successful in pinpointing key genes and microRNAs, such as CTSW, which could serve as novel genetic markers for earlier detection of the disease.
Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis.
Cell Mol Life Sci
January 2022
Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by chronic progressive pulmonary fibrosis and a poor prognosis. Genetic studies, including transcriptomic and proteomics, have provided new insight into revealing mechanisms of IPF. Herein we provided a novel strategy to identify biomarkers by integrative analysis of transcriptomic and proteomic profiles of IPF patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!